Renal denervation: Medtronic launches afib trial

Medtronic says it's launching a clinical trial evaluating renal denervation and cardiac ablation in treating atrial fibrillation.

Medtronic (NYSE:MDT) today said it's launching a study of a new, combination treatment for atrial fibrillation using renal denervation and cardiac ablation.

Medtronic

News Well, Clinical Trials, Cardiac Rhythm Management, Renal

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1JDrJPq